Method for preventing and/or treating the dysfunction and/or the lesion of nail structure, the plaster for its implementation and its application

FIELD: medicine, chemico-pharmaceutical industry.

SUBSTANCE: the present innovation deals with the plaster for the prophylaxis and/or the treatment of the dysfunction or the lesion of nail structure, especially, onychomycosis, ingrown nails, nail psoriasis, melanonychia of striate bodies and onychodystrophy, with application of the plaster mentioned and the ways of prophylaxis and/or treating the dysfunction and/or the lesion of nail structure due to application of the plaster mentioned. The latter is characterized by favorable therapeutic action onto the mentioned dysfunction or the lesion of nail structure, moreover, there is no necessity in drilling the foramen in the nail and/or in daily peeling the nail. The preferable variants deal with the plasters that contain hermetic protective layer and the layer fixed to the mentioned protective layer, moreover, the layer is in close contact with the nail and not obligatory with adjacent skin parts. The layer is made of the adhesive, the intensifier to penetrate skin and/or nail layer, therapeutic efficient quantity of sertaconasol as a free foundation and appropriate additives and/or additional pharmaceutically active agents.

EFFECT: higher efficiency of prophylaxis and therapy.

36 cl, 4 dwg, 6 ex



Same patents:

FIELD: chemical-and-pharmaceutical industry, biotechnology, medicine, in particular biologically active peptides with anti-microbial action.

SUBSTANCE: invention relates to peptides of general formula 1 (X1-Lys-Leu-X2-X3-X4-X5-X6-Arg-Lys-Ala-Ile-Ser-Tyr-Ala-Val-Lys-Ala-X2 (1) obtained by modification of starting structure of latarcin peptide, wherein X1 is absent or is glycine residue (Gly), or Phe-Gly dipeptide, or Leu-Phe-Gly tripeptide, or Gly-Leu-Phe-Gly tetrapeptide; X2 is glutamine residue (Gln) or isoleucyne residue (Ile); X3 is arginine residue (Arg) or lysine residue (Lys); X4 is arginine residue (Arg) or lysine (Lys) residue; X5 is lysine residue (Lys) or phenylalanine residue (Phe); X6 is glycine residue (Gly) or leucine residue (Leu); X7 is absent or is arginine residue (Arg), or Arg-Gly dipeptide, or Arg-Gly-Lys tripeptide, or Arg-Gly-Lys-His tetrapeptide, or Arg-Gly-Lys-Asn tetrapeptide.

EFFECT: new peptide with anti-microbial activity.

7 ex, 4 tbl, 3 dwg

FIELD: medicine.

SUBSTANCE: the present innovation deals with applying water-free warming lubricating compositions that contain multi-atomic alcohols, a gelatinization-inducing agent, a pH-regulating agent for treating fungous and bacterial infections and, also, with the methods to apply such compositions for warming, lubricating, introducing active ingredients and either preventing or treating fungous and bacterial infections. The innovation suggests nontoxic and nonirritating compositions being efficient for treating both fungous and bacterial infections.

EFFECT: higher efficiency of therapy.

10 cl, 11 dwg, 10 ex, 3 tbl

FIELD: medicine, dermatology.

SUBSTANCE: invention relates to using nitrogen oxide-producing components used for manufacturing a medicinal agent used in treatment or prophylaxis of subnail infection. Components comprise nitrite and organic acid. Before using each of indicated components is placed separately of one another. Nitrite is chosen from alkaline metal nitrites and earth-alkaline metal nitrites. Acid is chosen from formic acid, malic acid, maleic acid, acetic acid, lactic acid, citric acid, benzoic acid, tartaric acid, salicylic acid, ascorbic acid and their mixtures. At applying of indicated components on infected nail formed nitrogen oxides are able to penetrate through nail in the therapeutically effective dose. The effectiveness treatment index is similar or better as compared with oral treatment method but it shows lesser limitations with respect to safety including hepatotoxicity, severe cutaneous responses and interactions with other drugs.

EFFECT: improved method of treatment.

33 cl, 13 dwg, 16 tbl, 15 ex

FIELD: chemical-pharmaceutical industry, pharmacy.

SUBSTANCE: invention relates to the terbinafine (Lamisil®) solid medicinal formulation possessing high effectiveness and containing the enhanced doses of terbinafine. This provides decreasing the total dose of the preparation administrated by a course treatment. Proposed medicinal formulation represents tablets with cover or mini-tablets placed into capsules or sachet.

EFFECT: improved and valuable pharmaceutical properties of drug.

25 cl, 8 tbl, 1 dwg

FIELD: veterinary science, pharmacy.

SUBSTANCE: invention proposes a medicinal agent used in treatment of actinomycosis that comprises iodine preparations (iodine and potassium iodide) and sodium hypochlorite additionally. Using the claimed medicinal agent provides reducing treatment period up to 55% and diminishing the compelled slaughter up to 50%.

EFFECT: valuable veterinary properties and enhanced effectiveness of agent.

2 tbl, 2 ex

FIELD: medicine, pharmacy, fungicides.

SUBSTANCE: invention relates to a novel pharmaceutical composition as an ointment used in treatment of fungal diseases. Proposed composition comprises 3-methoxycarbonyl-5-(4-chlorobenzylidene)-thiazolidine-2,4-dione as active substance. Ointment comprises solid petroleum paraffin, stearic acid, vaseline oil and emulsion wax as a lipophilic base and benzoic acid as special additive. Pharmaceutical composition is prepared by fusion of solid components of a base followed by addition of 3-methoxycarbonyl-5-(4-chlorobenzylidene)-thiazolidine-2,4-dione concentrate in vaseline oil. Invention provides preparing pharmaceutical composition possessing high chemotherapeutic effectiveness and good tolerance and low toxicity that allows its using in treatment of dermatomycosis of different localization.

EFFECT: valuable medicinal properties of pharmaceutical composition.

2 cl, 2 tbl, 4 ex

FIELD: organic chemistry, fungicides, pharmacy.

SUBSTANCE: invention relates to a novel antifungal compound 2-(3,4-dimethyl-2,5-dihydro-1H-pyrrole-2-yl)-1-methylethyl pentanoate of the formula (I): that is prepared from plant, Datura metel. This compound elicits an antifungal activity and can be used in pharmaceutical composition.

EFFECT: valuable property of compound.

16 cl, 12 dwg, 3 tbl, 10 ex

FIELD: medicine.

SUBSTANCE: means contains methyl cellulose, sodium carboxymethyl cellulose, polyvinyl pyrrolidon glycerol, vinylin, 1% bifosin solution, pentol, nipagin and clean water.

EFFECT: prolonged action; high therapeutic effectiveness; accelerated treatment course; reduced risk of complications.

FIELD: medicine, dermatology, pharmaceutical industry, pharmacy.

SUBSTANCE: invention relates to an anti-fungal agent. Anti-fungal preparation comprises undecylenic acid and olive oil, clove carbon dioxide extract refined product prepared by distillation of clove carbon dioxide extract under vacuum under definite conditions wherein components are taken in the definite ratio. Proposed preparation promotes to effective treatment of cutaneous fungal diseases.

EFFECT: valuable medicinal properties of preparation.

4 tbl

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to anhydrous, antifungal, lubricating gel compositions comprising polyhydric alcohol, gelatinizing agent and an antifungal azole compound, and to a method for treatment of a patient with fungal infections comprising administration of indicated composition in a patient. Compositions shows the excellent warming and lubricating effect after its applying on skin and mucosal tissues and provides the effective treatment of fungal infections.

EFFECT: improved and valuable properties of compositions.

21 cl, 2 tbl, 11 dwg, 9 ex

FIELD: medicine.

SUBSTANCE: the suggested transdermal therapeutic system (TTS) includes adhesive matrix that contains biologically active substance - rotigotin. The adhesive matrix contains thermofusible contact glue, the latter consists of contact glue, the mixture of different contact glues or contact glue with a plastifier and at 160°C is of dynamic viscosity being 100 Pa·sec, not more. TTS has been obtained due to hot fusion technique: before stratifying the adhesive matrix its components should be fused and homogenized without usage of solvents at 70-200°C. According to the present innovation TTS has got high degree of filling with rotigotin which is released out of thermofusible matrices constantly and at therapeutically desirable rate. Rotigotin in case of carrying out the technique of hot fusion keeps its stability at heating up to 160°C. There is no necessity in applying, removing, regenerating or burning up organic solvents and providing corresponding safety measures during TTS manufacturing.

EFFECT: higher efficiency.

24 cl, 10 dwg, 10 ex, 4 tbl

FIELD: medicine.

SUBSTANCE: method involves applying plaster having sealing protection layer and contact layer attached to mentioned protection layer. The contact layer is directly engageable with nail and optionally with surrounding skin areas. The contact layer is manufactured from adhesive material, agent for stimulating penetration through skin and/or nail, therapeutically effective quantity of pharmaceutically active antifungal agent and permissible additives.

EFFECT: enhanced effectiveness of treatment.

21 cl

FIELD: medicine.

SUBSTANCE: system is applicable to skin surface.

EFFECT: improved flexibility and wear resistance.

7 cl, 3 dwg, 5 tbl

FIELD: medicine.

SUBSTANCE: invention describes a percutaneous or permucous medicinal formulation used in treatment of nicotine dependence or elimination from the smoking habit. Proposed medicinal formulation comprises nicotine, nicotinic salt, a derivative of nicotine or substance enhancing effect of nicotine in combination with at least one additional substance effecting on the central nervous system. Oral dosing an additional substance effecting on the central nervous system excludes adverse effects and providing a simple and safety intake of drug for patients.

EFFECT: improved and valuable properties of formulation.

10 cl

FIELD: medicine, pharmacy.

SUBSTANCE: invention describes a transdermal plaster for administration of fentanyl, alfentanyl, carfentanyl, lofentanyl, remifentanyl, sufentanyl or trifentanyl through skin and comprising a backing. Also, a reservoir is disposed on a backing and wherein proposed plaster displays an unregulated rate in administration of fentanyl, alfentanyl, carfentanyl, lofentanyl, remifentanyl, sufentanyl or trefentanyl through a patient skin in aims for analgesia for the prolonged time.

EFFECT: valuable medicinal properties of plaster.

85 cl, 4 tbl, 11 ex

FIELD: medicine.

SUBSTANCE: preparation is characterized by rapidly degrading or water-soluble plate in the environment, mainly consisting of one or several polymers soluble in water, and at least one active ingredient. The dosage form matrix is hardened foam in which empty spaces or cavities are available as a result of foaming soluble polymers in water containing foam-stabilizing substance differing from the active component. The cavities are filled with gas, gas mixtures or, preferably, with air. Dosage form thickness is 50 μm-5 mm large. Dosage form surface is rough or irregular, preferably made corrugated or zoned. Method involves producing plate-shaped dosage forms, distinguished by water-soluble polymers solution-, dispersion medium - or melt-foaming stages realization. The foaming stage is carried out as, for example, foaming film-forming polymer solution or dispersion medium by introducing gas or gas mixtures into it after having preliminarily added foam-stabilizing substances or by carrying out dissolved gas decompression, when needed, after adding foam-stabilizing substances, or by adding hydrophobic solvent which does not mix up with solvent, used for preparing water-soluble polymer solution or a dispersion medium with emulsion being produced, that contains hydrophobic solvent as finely dispersed drops. The solvent is the removed producing in this way foamed matrix structure, or by adding fillers or filler combinations, capable of gassing, or foaming water-soluble polymer melt by introducing gas or gas mixtures into it, or by receiving gas in chemical way, or by decompressing dissolved gas if needed, after having preliminarily added foam-stabilizing substances. A plate for introducing drugs is described with active ingredient selected from group composed of nicotine and nicotine bitartrate.

EFFECT: enhanced effectiveness of treatment; wide range of functional applications.

9 cl

FIELD: cosmetics, medicine, pharmacy.

SUBSTANCE: invention relates to compositions used in topical applying and possessing improved water-retaining properties and improved releasing of active agent. Proposed cosmetic compositions contain from 5% to 70% of pentane-1,5-diol by mass and cosmetically acceptable carrier and under condition that this composition doesn't contain polysiloxane, volatile siloxane, phosphatidylcholine, creatine, carnitine, pantenol, pyruvic acid, lauric acid monoglyceride or myristic acid monoglyceride. Also, invention discloses corresponding methods for administration, plaster for attachment of indicated composition to skin and methods for prophylaxis or treatment of skin dryness state or maintaining skin in moisture state. Compositions for topical using and administration of pharmaceutical preparation possess the improved water-retaining properties, improved releasing active agent being without toxicity and skin irritation.

EFFECT: improved and valuable medicinal properties of compositions.

37 cl, 5 tbl, 1 dwg, 6 ex

FIELD: medicine, stomatology.

SUBSTANCE: invention relates to agents and method for whitening teeth. Agent for whitening teeth represents a film made of combined hydrophobic and hydrophilic layers. Hydrophilic layer comprises hydrogen peroxide or its complexes with organic, inorganic polymeric compounds and fluoride-containing compounds, and/or potassium nitrate. Accessory components are included in both hydrophilic and hydrophobic layers of film wherein the content of a whitening component is 1.2-1.5 mg/cm2 as measured for hydrogen peroxide, and the film thickness is 0.2-0.6 mm. For whitening teeth this film is glued on the moister frontal surface of teeth row by gums line for 2-4 h. Agent and method for whitening don't show irritating effect in mouth cavity tissues, injury of teeth or destruct teeth enamel.

EFFECT: improved and valuable properties of agent and method.

7 cl, 16 ex

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to porous spongy cellulose material for its using in treatment of wounds and/or burns. Cellulose material comprises zinc, copper, selenium and/or iron bound with the matrix material and/or absorbed on its in the amount providing granulation and revascularization processes of the wound base wherein the amount of zinc, copper, selenium and/or iron is at least 0.1 mcg/g of dry material. The porous spongy cellulose material is effective by consumptions for its preparing and can be used easily in treatment of wounds and/or burns.

EFFECT: enhanced effectiveness and valuable medicinal properties of material.

12 cl, 3 ex

FIELD: medicine.

SUBSTANCE: invention proposes using percutaneous therapeutic system inducing high plasma levels of rotigotin for producing anti-parkinsonic medicinal agent and a method for treatment of Parkinson's disease. Proposed system involves rotigotin in the concentration from 0.1 to 3.15 mg/cm2 in form of free base and silicone representing a mixture of at least one pressure-sensitive stick silicone adhesive (Q7-4301) and at least one pressure-sensitive silicone adhesive with mean stickness (Q7-4201). This provides an average plasma concentration of rotigotin from 0.4 to 2.0 ng/ml for 24 h after its applying.

EFFECT: enhanced medicinal effectiveness of system.

10 cl, 2 tbl, 1 ex

FIELD: organic chemistry.

SUBSTANCE: invention relates to new benzopyran-4-ones of formula , wherein R1 is benzyl, chlorobenzyl, methylbanzyl, methoxybenzyl, cyanobenzyl, etc.; R2 and R2' are independently hydrogen, C1-C4-alkyl; substituted C1-C4-alkyl; R12 is -N(R4)(CO R3); R3 is phenyl optionally substituted with C1-C4-alkyl; R4 is C1-C4-alkyl optionally substituted with amino group; R5, R6, and R7 are hydrogen; R7 is hydrogen, halogen, hydroxy, C1-C4-alkoxy, and cyano; as well as specific stereoisomers thereof and stereoisomer mixtures. Also disclosed is pharmaceutical composition based on said compounds, method for modulation of KSP kynezine activity and using of said compounds in production of drugs for treatment of cell proliferative diseases.

EFFECT: new compound with pharmaceutical activity.

19 cl, 3 dwg, 4 tbl, 26 ex